17h
Fin vs Fin on MSNZealthy vs Ro: Which Weight Loss Plan Works Best?Zealthy and Ro both offer FDA-approved, generic GLP-1s at personalized dosages to fit your needs. These platforms also have a ...
An abrupt aversion to sex is a common, albeit lesser-known, complication of taking GLP-1 medications, such as Mounjaro, ...
Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.
If the CMS rule to cover obesity medications is finalized, coverage will increase by other insurers, experts predicted. HHS ...
A recent study suggests a potential link between Ozempic and vision loss, particularly non-arteritic anterior ischemic optic ...
The main results of the SUMMIT trial, reported last year, showed that tirzepatide—a dual glucose-dependent insulinotropic ...
There's growing evidence to suggest that GLP-1 drugs, which include semaglutide, may be useful for treating alcohol use disorder.
An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use of “affordable” compounded weight loss drugs.
Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance ...
In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...
We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...
Viking Therapeutics is a clinical-stage biotech company focused on developing weight-loss therapies. Read why I rate VKTX ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results